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Abstract  1 
 2 
Knowledge of how the joint functions as an integrated unit in health and disease 3 
requires an understanding of the stromal cells populating the joint mesenchyme, 4 
including fibroblasts, tissue resident macrophages and endothelial cells. 5 
Physiological and pathological mechanisms in these mesenchymal cells that define 6 
the joint have begun to cast new light on why joint inflammation persists.  In this 7 
review, we highlight how the shared embryological origins of fibroblasts and 8 
endothelial cells may shape the behaviour of these cell types in diseased adult 9 
tissues. We review the molecular mechanisms by which cells of mesenchymal origin 10 
sustain inflammation in the synovial membrane and tendons, highlighting the 11 
importance of recently discovered fibroblast subtypes and their associated cross talk 12 
with endothelial cells, tissue resident macrophages and leukocytes. Finally, we 13 
discuss how this knowledge shapes the future therapeutic landscape, emphasising 14 
the requirement for new strategies to address the pathogenic stroma and associated 15 
cross talk of leukocytes with cells of mesenchymal origin.  16 
 17 
Key points 18 
 19 
 Joint inflammation and tissue damage are mediated by stromal cells derived 20 
from of embryonic mesodermal origin  21 
 Stromal activation and inflammation “memory” of previous inflammatory 22 
insults  are shared disease mechanisms exhibited by fibroblasts, tissue 23 
resident macrophages and  and endothelial cells 24 
 Recent advances characterising the phenotype and function of cells of 25 
mesenchymal origin highlight thee distinct fibroblast subtypes mediatinge joint 26 
inflammation and tissue damage 27 
 Mesenchymal stromal cell niches and their interactions with leukocytes are 28 
implicated in the persistence of joint inflammation  29 
 To be effective, strategies to treat residual joint disease should target 30 
pathogenic stroma and associated immune cell cross talk  31 
 32 
 33 
 3 
Introduction 34 
 35 
Chronic inflammatory diseases affecting joint soft tissues include arthritis 36 
(synovium and cartilage), enthesopathy and tendinopathy. Collectively, these 37 
diseases  comprise a significant global economic burden1. Each are characterized 38 
by inflammation of mesenchymal tissues that form the synovium, tendons, 39 
ligaments and joint capsule and in some cases structural damage to bone and 40 
cartilage. Inflammation of these tissues is broadly characterized by leuckocyte 41 
infiltration, fibroblast accumulation and neovascularization supporting cell 42 
expansion. In this article, we first review the pathophysiological basis of 43 
inflammation and tissue damage with respect to the embryological origins of joint 44 
mesenchymal tissues. We next discuss the stromal cell types populating joint 45 
mesenchymal tissues, including fibroblasts, tissue resident macrophages (TRM) 46 
and endothelial cells (vascular and lymphatic),  highlighting their contribution and 47 
roles in chronic synovial inflammation and tissue damage. Finally, we discuss 48 
potential future therapeutic strategies to target inflammation across joint 49 
mesenchymal tissues that address the pathogenic stroma and associated immune 50 
cell cross talk.  51 
 52 
1.0 Embryological origins of the tissues that mediate inflammation 53 
and damage across the whole joint organ  54 
 55 
Inflammation and tissue damage are pivotal pathological processes affecting tissues 56 
structures across the whole joint organ. To further understand the mechanisms and 57 
inter-relationships underpinning these fundamental disease processes, it is important 58 
to consider the origins of joint tissues, given that an organ is best defined by its 59 
embryological origin as well as function.  This section discusses how the 60 
embryological and anatomical origins of the tissues that comprise the joint might 61 
shape inflammation and tissue damage, highlighting how this knowledge informs 62 
understanding of ‘disease patterns’ across the joint.  63 
 64 
The anatomical basis of inflammation and tissue damage relative to their 65 
embryological origin is summarized in Figure 1. Although parts of the axial skeleton 66 
 4 
derive from neural crest, Embryonic mesoderm is the precursor for mesenchymal 67 
tissues comprising the axial and appendicular skeleton, synovium, cartilage, 68 
tendons, ligaments, joint capsule and their associated lymphatics and vasculature. 69 
These joint soft tissues are predominantly composed of cells of mesenchymal origin, 70 
including fibroblasts, vascular and lymphatic endothelial cells and TRM. The shared 71 
embryological origins of  stromal fibroblasts and endothelial cells may shape the 72 
behaviour of these cell types in diseased adult tissues. Notably, mesoderm derived 73 
fibroblast and endothelial cell populations both undergo sustained phenotypic 74 
changes after exposure to inflammatory stimuli, exhibiting stromal activation and a 75 
form of tissue ‘memory’2,3. However, the distinct molecular markers expressed by 76 
these cell types vary, as we later discuss.   TRM also exhibit complex activation 77 
states and “memory”4. The origins and renewal of TRM have been extensively 78 
reviewed and will not be repeated here 5-8. The majority of TRM are established 79 
during embryonic development and persist into adulthood, rather than replacement 80 
from circulating adult monocytes 7,9-14. During early gestation, macrophages are first 81 
observed and expand in the extraembryonic yolk sac during primitive hematopoiesis. 82 
Yolk sac derived hematopoietic stem cells (HSCs) emerge to form bone marrow 83 
precursor cells, which subsequently gives rise to all immune cell lineages 7,15 (Figure 84 
1). Importantly, yolk sac derived TRM are phenotypically distinct from HSC derived 85 
progeny 10. The subspecialized adult tissue niches which TRM occupy dictate 86 
heterogeneity in the phenotype and functions of these cells in health and disease 16. 87 
We next review how these mesenchymal cell populations are implicated in mediating 88 
inflammation and tissue damage in joint disease.  89 
 90 
2.0 Cells of mesenchymal origin in the healthy and diseased joint 91 
 92 
In this section, we focus exclusively on cells of mesenchymal origin including 93 
fibroblasts, endothelial cells and TRM rather than on haematopoietically derived cells 94 
whose role in these processes (in particularly inflammation and damage) has been 95 
well documented17-19. We discuss the roles of these cells in normal joint physiology 96 
and their impact on inflammation and damage in joint disease. We highlight the 97 
recently identified mechanisms implicated in sustaining synovial inflammation, 98 
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discussing the molecular features and pathological phenotypes of fibroblast 99 
subtypes, endothelial cells and TRM.  100 
2.1 Fibroblasts and the healthy joint 101 
 102 
The term ‘stroma’ was originally derived from the Greek word describing “a platform 103 
on which to lie” and is used to describe the supporting substance of tissue. Its 104 
principle role is to maintain the microenvironment required by the parenchyma; the 105 
important functional elements of each body system. The stroma comprises 106 
connective tissue, nerves, vessels and the extracellular matrices (ECM) and fluids 107 
which these cells produce20. Joint soft tissues including synovium, capsule, tendon 108 
and enthesis are predominantly composed of mesenchymal stromal cellscomprised 109 
of cellular and acellular ECM. Fibroblasts are the most abundant cell type populating 110 
these joint connective issues21 and synthesise the highly organized collagen rich 111 
scaffold necessary for joint structure and movement.  112 
 113 
Fibroblasts are defined by their spindle shaped morphology, the absence of specific 114 
lineage markers of leukocytes, endothelium and epithelium and their ability to adhere 115 
to tissue culture plastic in vitro22. They are believed to arise from 3 distinct cellular 116 
origins: primary mesenchyme, local epithelial-mesenchymal transition (EMT) or bone 117 
marrow derived precursors (circulating fibrocytes)23,24. It is widely accepted that the 118 
majority of fibroblasts originate from primary mesenchymal cells and that fibroblasts 119 
can proliferate to generate new progeny25,26. In physiological conditions, fibroblasts 120 
provide mechanical strength to tissues by producing ECM  components  (type I, III 121 
and V collagen and fibronectin) as well as factors that regulate ECM turnover, 122 
including metalloproteinases (MMPs) and proteins involved in the formation of 123 
basement membranes (type IV collagen and laminin)27,28. Fibroblasts synthesise an 124 
array of paracrine factors29 and exhibit mechanosensitive properties30 to effect 125 
functional adaptation in normal joint physiology. The intimate relationship between 126 
fibroblasts and mesenchymal stromal cells (MSC) and the clinical use of MSC to 127 
repair damaged tissues has driven a renewed interest in fibroblasts as new 128 
therapeutic targets21.  129 
 130 
2.2 Mechanisms sustaining joint inflammation based on pathogenic stroma 131 
 132 
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2.2.1 Fibroblasts and the diseased joint 133 
 134 
Traditionally, the diversity of stromal cells and in particular fibroblasts and their roles 135 
beyond those of space filling and ECM homeostasis have been underexplored in 136 
inflammation. Mesenchymal tissues in the joint including the synovium, capsule, 137 
enthesis and tendons undergo phenotypic changes as a consequence of 138 
inflammation31-33. These include molecular and structural changes to the ECM, 139 
impacting upon the functional quality of the healed tissue34. Whilst it remains 140 
challenging to discern which is the initiating pathogeneic cell type, it is clear that 141 
stromal cells populating these tissues provide a niche conducive to sustaining 142 
chronic inflammation2,35,36. Recent work shows that fibroblasts vary phenotypically 143 
and functionally at different anatomical sites and contribute significantly to the 144 
identity of individual tissues, providing a so-called ‘stromal postcode’26. Furthermore, 145 
it is known that, rather than acting as a bystander, fibroblasts are capable of actively 146 
participating and indeed orchestrating inflammation and immunity36-38. We next 147 
review how fibroblasts sustain inflammation, highlighting the mechanisms 148 
underpinning their activation, “memory” and phenotypic diversity, with particular 149 
focus on the synovial microenvironment.  150 
 151 
Fibroblast activation and memory 152 
 153 
Fibroblast activation is a recognized feature of diseases affecting the joint, whereby 154 
fibroblasts adopt a pro-inflammatory phenotype. This pathological feature has been 155 
identified in cancer 39, rheumatoid synovium32,33 and tendon disease31. Fibroblast 156 
activation and memory therefore span boths innate and adaptive immune responses, 157 
suggesting this is a highly conserved disease mechanism common to tissues of 158 
mesenchymal origin. There is now a growing list of cell surface molecules and 159 
secreted products which collectively provide a fibroblast activation marker “cassette”. 160 
These include CD90 (Thy1), CD44, decay accelerating factor (CD55), VCAM-1 161 
(CD106), uridine diphosphoglucose dehydrogenase, and prolyl-4-hydroxylase, 162 
Podoplanin (PDPN/gp38), endosialin (CD248) and Fibroblast Activation Protein 163 
(FAP) 31,36,37,40-42. Fibroblast activation markers therefore represent important 164 
phenotypic alterations implicated in effecting the switch from resolving to persistent 165 
inflammation 42.  166 
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 167 
Epigenetic changes are implicated in fibroblast activation and memory.  New insights 168 
into the epigenetics of inflammatory rheumatic diseases have been recently 169 
reviewed in detail elsewhere 43. Prolonged exposure of RA synovial fibroblasts to 170 
TNF reduce histone H4 levels and promote H4 acetylation 44. This study showed 171 
that TNF removed the chromatin barrier from the CXCL10 promoter, permitting 172 
abundant binding of NF-B family transcription factors and recruitment of 173 
transcriptional machinery44. DNA methylation is another important epigenetic 174 
modification identified in RA synovial fibroblasts occurring during the early stage of 175 
disease 45. Further studies are required to identify the mechanisms underpinning 176 
DNA methylation and there appears to be important prognostic potential for 177 
differentially methylated genes as disease biomarkers 45. The activated and 178 
aggressive phenotype of RA synovial fibroblasts is associated with global DNA 179 
hypomethylation46. Gaur et al. investigated if microRNAs moderate the methylation 180 
status of RA synovial fibroblasts, showing L-methionine increased DNA methylation 181 
compared to betaine 47. Collectively these studies advance our understanding of how 182 
epigenetic changes are implicated in fibroblast activation and memory, informing 183 
future strategies to selectively target pathogenic fibroblasts. 184 
Recent work shows that tissue resident fibroblasts help define the pattern of joints 185 
involved, not only in arthritis but in other diseases with a prominent stromal 186 
component39.  187 
Importantly, this concept of epigenetically-driven anatomical diversity of synovial 188 
fibroblasts provides an attractive mechanism to explain the clinical observations that 189 
different types of arthritis affect distinct types of joints. For example, OA and PsA 190 
often involve the distal interphalangeal joints, whereas RA is frequently symmetrical 191 
and more commonly affects the MCP joints. In contrast, AS mainly targets spinal 192 
ligaments and entheseal tissue40. Such studies have prompted improved 193 
characterization of the phenotypes of fibroblast subsets and their different proposed 194 
roles. In RA, synovial fibroblasts undergo distinct changes in function, including loss 195 
of immunosuppressive response in early disease, followed by later acquisition of an 196 
immuno-stimulatory phenotype41. 197 
 198 
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Fibroblasts from different joint tissues maintain their phenotype, positional memory 199 
and topographic differentiation despite culture ex vivo. Fibroblasts isolated from RA 200 
synovium or diseased tendon exhibit stromal ‘memory’, whereby these cells show an 201 
enhanced subsequent capacity to respond to an additional  inflammatory stimulus 202 
2,31,44. Therefore, sustained expression of activation markers by fibroblasts in the joint 203 
reflects their ‘primed’ status after exposure to an inflammatory stimulus. In addition to 204 
fibroblast activation, this concept of stromal memory also spans innate and adaptive 205 
immunity, suggestive of a highly conserved disease mechanism across tissues of 206 
mesenchymal origin. The processes underpinning innate memory have been 207 
extensively reported for leukocytes 48,49 and are gaining acceptance in tissue 208 
resident cells of mesenchymal origin. Engagement of TLR4 and downstream 209 
activation of the NFB pathway is a prominent pathological feature of fibroblasts 210 
populating inflamed joint tissues 2,31,44. These studies suggest that fibroblast memory 211 
is associated with altered NFB responsiveness to an inflammatory stimulus  50. 212 
Given the longevity of fibroblasts as tissue resident cells and the relatively low rates 213 
of tissue cell turnover in the joint 51, the effects of stromal memory in tissues such as 214 
synovium and tendon are likely to be  long lived. In contrast, dermal fibroblasts show 215 
higher rates of turnover and do not exhibit stromal memory, suggesting this disease 216 
mechanismprocess of stromal memory may vary according to anatomical location 217 
2,52,53. Rheumatic diseases follow a characteristic anatomical pattern of joint and 218 
organ involvement. Mechanisms regulating the predilection of specific joints for 219 
developing particular forms of arthritis (for example osteoarthritis (OA) compared to 220 
rheumatoid arthritis (RA)) have been reviewed in detail 54. These include site-specific 221 
local cell types driving disease, systemic triggers affecting local cell types and site-222 
specific exogenous factors activating cells locally. Therefore the mechanisms 223 
underpinning activation of stromal cells depends on the local anatomical tissue 224 
niche54. 225 
 226 
Fibroblast diversity  227 
Recent work shows that tissue resident fibroblasts help define the pattern of joints 228 
involved in RA 55,56. The concept of epigenetically-driven anatomical diversity of 229 
synovial fibroblasts provides an attractive mechanism to explain the clinical 230 
observations that different types of arthritis affect distinct types of joints. For 231 
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example, OA and PsApsoriatic arthritis  often involve the distal interphalangeal joints, 232 
whereas RA is frequently symmetrical and more commonly affects the MCP joints. In 233 
contrast, ASankylosing spondylitis (AS) mainly targets spinal ligaments and 234 
entheseal tissue57. Such studies have prompted improved characterization of the 235 
phenotypes of fibroblast subsets and their different proposed roles. In RA, synovial 236 
fibroblasts undergo distinct changes in function, including loss of 237 
immunosuppressive response in early disease, followed by later acquisition of an 238 
immuno-stimulatory phenotype58. Fibroblasts show considerable variability according 239 
to genetic and hormonal factors between individuals  Highly conserved homeobox 240 
(HOX) transcription factors specify regional identities of cells and tissues 241 
throughout the body 59,60 and adult fibroblasts retain key features of embryonic 242 
positional HOX gene expression 56. Fibroblasts also vary according to their 243 
anatomical location in relation to tissue structures at an individual site and the 244 
exogenous stimuli which they receive 54,56,61. Whether variability can be attributed to 245 
the plasticity of individual fibroblasts necessary for responding to different 246 
environmental cues and whether phenotypic variation can be used to define distinct 247 
subsets of fibroblasts specialized for different niches remains unclear.  248 
 249 
The synovium is composed of lining and sub-lining layers of fibroblasts which vary in 250 
terms of phenotype and function according to their anatomical sub-location. Single 251 
cell RNA sequencing and immunohistochemistry have revealed that RA synovial 252 
fibroblasts can be broadly characterized into 3 subsets, highlighted in Figure 2. 253 
Synovial lining fibroblasts are CD34-CD90-CD55+ and Cadherin 11+. This lining 254 
subset synthesizes MMP-1 and MMP-3 which mediate tissue damage in the 255 
inflamed joint 62. Fibroblasts populating the synovial sublining are predominantly 256 
comprised of 2 populations. CD34+CD90- fibroblasts release CXCL12, CCL2 and IL-257 
6 and mediate drive fibroblast accumulation cell proliferation and invasion. A second 258 
population of CD34-CD90+ fibroblasts with a pro-inflammatory phenotype highly 259 
express markers of stromal fibroblast activation 62,63. These ‘pathogenic’ fibroblast 260 
subsets between them degrade articular cartilage, mediate stromal memory, sense 261 
tissue damage via TLR4 activation and have altered responsiveness to signalling 262 
pathways converging on NFB responsiveness26,33,50,62 (Figure 2). Having 263 
highlighted the complexity of discrete synovial fibroblast subtypes, we next discuss 264 
Comment [MOU1]: Chris can you 
suggest a reference for this 
statement? 
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the phenotypes and functions of other mesenchymal cell types including endothelial 265 
cells and TRM and their respective roles in joint health and disease.  266 
 267 
2.2.2 The endolymphatic niche in the healthy and diseased joint  268 
 269 
Other mesenchymal stromal tissues including the vasculature and lymphatics 270 
contribute to sustaining inflammation across the joint organ. Neo-angiogenesis is a 271 
prominent feature of disease of mesenchymal joint tissues and impacts upon 272 
changes in tissue architecture and pain perception64. In health, vascular endothelial 273 
cells regulate blood flow, vessel wall permeability and leukocyte extravasation into 274 
tissues, regulating the inflammatory process 65-68. In lymph nodes and tertiary 275 
lymphoid tissues, high endothelial vessels (HEVs) provide specialized 276 
microenvironments for efficient entry of lymphocytes into tissues in an L-selectin 277 
dependent process69. The phenotypes of endothelial cells change as inflammation 278 
transitions from acute to chronic and also between activation of innate and adaptive 279 
immune systems 67. Endothelial cell phenotypes are poorly characterized in tendon 280 
and entheseal tissues. However, in RA synovium, these cells have been described 281 
as activated, angiogenic, apoptotic and leaky, a process found in many tumour 282 
microenvironments 70. During prolonged exposure to inflammatory stimuli endothelial 283 
cells become activated, exhibit memory and express adhesion molecules including 284 
ICAM, VCAM-1 and CD31 (PECAM-1)  3,71-73 (Figure 2). These activated endothelial 285 
cells subsequently also present chemokines and initiate leukocyte migration from 286 
blood to local tissues70. Endothelial activation is a cause and consequence of 287 
endothelial dysfunction74,75, culminating in increased microvascular permeability, 288 
extravasation of plasma and joint oedema. Release of angiogenic factors including 289 
VEGF triggers angiogenesis, provide necessary nutrients and oxygen to meet the 290 
metabolic demands of the inflamed tissue. Importantly, neo-angiogenesis further 291 
promotes the retention and survival of immune cells at inflamed sites, thereby 292 
sustaining chronic inflammation 38. These angiogenic processes occur during normal 293 
inflammatory immune responses (i.e vaccination)76, however whether angiogenesis 294 
that occurs in joint disease is a cause or effect of pathology remains unclear. 295 
 296 
Stromal lymphatic vessels form a one-way conduit for tissue fluid and leukocytes in 297 
health and disease 77. During adaptive immune responses, antigen presenting cells 298 
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travel to lymph nodes via lymphatic vessels, which highly express PDPN, implicated 299 
in stromal fibroblast activation78. The permeability of lymphatic vessels is a tightly 300 
regulated dynamic process that alters during health and disease 79. Lymphatic 301 
vessel growth (lymphangiogenesis) is a primary response during acute inflammation, 302 
which becomes dysregulated in chronically inflamed adult tissues80. In experimental 303 
murine models of inflammatory arthritis, lymphatic vessels and nodes draining the 304 
diseased joint undergo an initial expansion phase to expedite lymphatic clearance. 305 
This expansion phase is followed by a collapsed phase, characterized by structural 306 
damage to lymphatic vessels and reduced lymphatic clearance 79,81. Studies 307 
demonstrate alteration in lymphatic vessel function and lymph node volume also 308 
occur in patients with RA flare 82. Therapies targeting aberrant lymphatic function 309 
have shown promise in preclinical models of inflammatory arthritis and may prove 310 
efficacious in RA 79.  311 
 312 
2.2.3 Tissue Resident Macrophages in the healthy and diseased joint 313 
 314 
TRM mediate a diverse range of biological actions. They are appropriately positioned 315 
and transcriptionally primed to respond to local environmental challenges, 316 
maintaining tissue homeostasis. TRM direct immune surveillance, induce 317 
inflammation and promote subsequent resolution, reviewed in detail elsewhere 34,83. 318 
Given the biological complexity of these roles, TRM are highly heterogeneous and 319 
exhibit diverse phenotypic and functionally distinct subtypes within a single tissue 320 
type 5,84.  321 
 322 
In inflamed synovium, TRM mediate immune surveillance through expression of a 323 
variety of pattern recognition receptorsDAMPs, notably Toll-like receptors (TLR) 324 
TLR2 and TLR4 and facilitate the recruitment of infiltrating leukocytes, incuding 325 
monocyte derived macrophages 85-87. TRM induce joint inflammation through release 326 
of TNF, IL-1 IL-6, GM-CSF and PGE2, driving fibroblast accumulationproliferation, 327 
angiogenesis, leukocyte recruitment and tissue damage via protease secretion 328 
(Figure 2). The essential role of non-classical Ly6C-monocytes has been reported in 329 
murine arthritis models 88. This study highlights the phenotypic heterogeneity of 330 
synovial TRM, demonstrating how macrophage activation status regulates disease 331 
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progression and resolution. In support of this, human RA synovial macrophages 332 
exhibit distinct transcriptional profiles associated with disease activity and therapy 89. 333 
However, distinction between TRM and infiltrating macrophages is currently 334 
hampered by a lack of specific markers that distinguish between these populations in 335 
diseased human tissues.  336 
 337 
The pro-inflammatory milieu in the inflammed synovium triggers an active process of 338 
lipid mediator class switching and the subsequent release of families of specialized 339 
proresolving mediators (SPM). These include lipoxins, resolvins, protectins and 340 
maresins, that are generated via transcellular biosynthesis and are concerned with 341 
mediating resolution of inflammation90-94. These bioactive lipid mediators initiate 342 
programmes which halt neutrophil infiltration, potentiate monocyte recruitment, 343 
moderate vascular permeability and promote phagocytosis and drainage of apoptotic 344 
cells95. The mechanisms mediating resolution in inflammatory arthritis have been  345 
reviewed in detail and are not covered here are reviewed in detail elsewhere 96. TRM 346 
are key regulators of repair and fibrosis across all tissue types 34 and are also 347 
implicated in mediating resolution of inflammation. Distinct populations of resolution 348 
phase macrophages have been identified in systemic murine inflammation models 349 
that express Alox15, Timd4 and Tgfb2, which terminate leukocyte recruitment and 350 
promote clearance 97. However, the precise phenotypes of TRM mediatingeffecting 351 
resolution in human joint disease requires further investigation.  352 
 353 
 354 
 355 
2.2.4 Cross talk between cells of mesenchymal origin  356 
 357 
Having highlighted the molecular features and phenotypes of mesenchymal cells  358 
and their roles in mediating joint pathology, we next discuss how cross talk between 359 
these cell populations sustains inflammation. Damage sensing mechanisms, 360 
cytokine and chemokine gradients are pivotal pathological processes involving cross 361 
talk between fibroblast, endothelial cell, TRM and leukocyte populations that sustain 362 
inflammation in the diseased joint 26,98,99.  363 
 364 
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RA synovial fibroblasts act as sentinel cells that can “sense” tissue damage. This 365 
occurs via the binding of damage associated molecular patterns (DAMPs) including 366 
HMGB1, heat shock and S100 proteins100,101. Tenascin-C a matrix protein induced 367 
upon tissue damage also activates TLR4 mediated sterile inflammation 102. Binding 368 
of these ligands to TLR4 induces a high alert state, favouring the development of 369 
chronic inflammation 50,103. Engagement of TLR4 activates Myd88 signalling 370 
pathways, inducing pro-inflammatory cytokine release via NFB activation 48.  371 
Consequently, activated synovial fibroblasts are primed to release a broad range of 372 
pro-inflammatory mediators. These localised cytokine and chemokine gradients 373 
promote the migration, retention and survival of leukocytes and TRM,42,104 creating a 374 
complex functional syncytium conducive to sustaining inflammation, highlighted in 375 
Figure 3. The processes mediating leukocyte trafficking between stromal 376 
compartments in RA are recently reviewed in detail elsewhere 105. 377 
 378 
Fibroblast – immune cell cross talk 379 
 380 
RA synovial fibroblasts promote leukocyte retention via release of cytokines and 381 
chemokines and via contact with other cells of mesenchymal origin. Pro-382 
inflammatory cytokines released by retained monocytes, T cells and TRM including 383 
IFN, TNF and IL-1 induce activated synovial fibroblasts to release high levels of 384 
PGE2, GM-CSF, IL-6. These cytokines exert differing effects on leukocyte activation. 385 
PGE2 moderates chemokine production and promotes Th2, Th17 and Treg 386 
responses 106. IL-6 drives CD4+ T cells towards Th17 activation 107, whereas  GM-387 
CSF promotes neutrophil survival and monocyte differentiation in the inflamed 388 
synovium 26,108. Nguyen et al. demonstrated that IL-6 and other inflammatory 389 
cytokines and chemokines are regulated by a positive feedback loop that selectively 390 
operates in fibroblasts involving leukemia inhibitory factor (LIF), LIF receptor and 391 
STAT4 109. TGF, also found at high levels in RA synovium induces persistent 392 
expression of CXCR4 on synovial T cells, leading to their active CXCL12 mediated 393 
retention, providing an additional mechanism for immune cell retention 110. RA 394 
synovial fibroblasts also release a repertoire of chemokines, generating a gradient 395 
consisting of CCL2, CCL4, CCL5, CCL8, CXCL8, CXCL12 and IFN 26,111,112. This 396 
chemokine gradient actively promotes the recruitment, retention and survival of 397 
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monocytes and CD4+ T cells at the inflamed synovial site (Figure 3). CXCL12, 398 
VCAM-1 (CD106) and IL-6 therefore constitute part of a ‘stromal address code’, 399 
critical for leukocyte survival and differentiation 26. 400 
 401 
Endothelial cell cross talk  402 
 403 
Resident stromal cells populating inflamed synovium modulate the ability of 404 
endothelial cells to recruit leukocytes via release of soluble mediators or direct cell-405 
cell contact.  Stromal Fibroblasts isolated from healthy patients are known to 406 
regulate the cytokine-sensitivity of vascular endothelium, while fibroblasts associated 407 
with chronic inflammation adopt a pro-inflammatory phenotype 29,113. Cytokine and 408 
chemokine gradients mediate and sustain cross talk between endothelial cell, 409 
synovial fibroblast and TRM populations. IL-6, TGF1 and VEGF released from TRM 410 
provide the necessary cues to promote an angiogenic environment required to 411 
sustain endothelial cell activation and dysfunction (Figure 3). This is supported by 412 
antibody neutralisation of IL-6, which diminished the ability of endothelial cells to bind 413 
lymphocytes in co-cultures with RA fibroblasts 29.  414 
 415 
The RA synovial fibroblast milieu further sustains an angiogenic environment through 416 
chemokine gradients comprising CXCL1-5 and CXCL8 26 (Figure 3). RA fibroblasts 417 
regulate expression of endothelial cell adhesion molecules, potentiate leukocyte 418 
extravasation 58 and induce unstimulated HUVEC to bind flowing lymphocytes via a 419 
CXCR4-CXCL12 dependent manner 29. Consequently, the interactions between cells 420 
of mesenchymal origin create and sustain an inflammatory milieu, whereby synovial 421 
inflammation persists and potentially becomes independent of its inciting cause. We 422 
next consider how persistent inflammation culminates in tissue damage across soft 423 
tissues that comprise the joint.  424 
 425 
2.3 Mesenchymal cells and their role in joint damage   426 
 427 
In health, early damage repair mechanisms maintain the integrity of joint soft tissues. 428 
In joint disease, sustained inflammation, tissue remodeling and fibrosis ensue,  429 
resulting in irreversible tissue damage. We next discuss how cells of mesenchymal 430 
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origin mediate fetal scarless healing and highlight the mechanisms by which they 431 
induce damage across adult joint tissues.  432 
In contrast to normal adult tissues, early human and murine fetal wounds and 433 
wounds in Nude (FoxN1 deficient) mice heal without scar formation114. Fetal wounds 434 
show diminished numbers of immune cells and lower levels of cytokines compared 435 
to adult tissues 115-118. Differences between embryonic and adult tissue healing are 436 
also attributed to the milieu of pro-fibrotic growth factors released by TRM, including 437 
those of the TGF family. TGF1 levels are reduced and this growth factor shows 438 
accelerated clearance in embryonic compared to adult tissue repair 119-121. 439 
Collectively these studies indicate a role for immune  cell derived cytokines including 440 
TNF and TGF in tissue scarring and healing122. Other studies highlight differences 441 
between fetal and adult fibroblasts and localized production of MMP-9 and MMP-13 442 
in the scarring process 114. Fetal fibroblasts show enhanced synthetic function, 443 
increased rate of turnover of collagen, hyaluronic acid, ECM components and 444 
increased migration velocity compared to adult fibroblasts, suggesting rapid healing 445 
may also play a role in scarless tissue repair123-125.  446 
In adult tissues, fibroblasts and TRM directly contribute to joint destruction, bony 447 
erosions and remodeling through expression of enzymes such as MMPs126. MMP-2, 448 
MMP-9 and MMP-13 have been specifically implicated in the pathogeneis of RA and 449 
OA127. MMP-9 is also upregulated by CXCL12 (SDF-1) a key chemokine secreted by 450 
synovial  fibroblasts128. FAP is highly expressed within RA synovium and co-localises 451 
with MMP-13, where it appears to play a role in tissue degradation129.  Cathepsins, a 452 
major group of proteases involved in joint remodeling are also upregulated in the 453 
diseased joint130. Additionally fibroblasts can indirectly contribute through cross talk 454 
with TRM and lymphocytes, further amplifying processes driving tissue damage 455 
(Figure 3), whilst also presenting antigen to tissue infiltrating lymphoctyes131. 456 
 457 
Pathological conditions in which cells of mesenchymal origin play a role include 458 
chronic inflammation (e.g. RA, chronic skin wound healing), tissue fibrosis (e.g. 459 
COPD) and cancer (e.g. breast cancer).  Interestingly, while these diseases differ 460 
dramatically in aetiology and genetic predispositions, they converge in terms of 461 
phenotype and function of the stromal component. Fibroblasts expand in the RA 462 
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synovial tissue and in the tumor parenchyma, while fibrosis is characterized by 463 
profound changes in myofibroblast phenotype and function across different organs 464 
such as the lungs and kidneys 132. Whether these fibroblast properties are intrinsic 465 
phenotypic changes acquired as a consequence of exposure to chronic 466 
inflammation, or are derived from the conditioning of the pathogenic infiltrating cells 467 
is still under investigation and seems to differ in the different conditions37. Lafevre et 468 
al reported epigenetically programmed aggressive cells may “spread” arthritis from 469 
inflamed to uninflamed joints in the early stages of disease, 133. PDPN expressing 470 
lining synovial fibroblasts are migratory and mediate release of cartilage destructive 471 
MMPs 33,62. Collectively, these data raise the possibility of distinct mesenchymal cell 472 
subsets implicated in mediating the effects of tissue damage in the diseased joint. 473 
We next discuss how the possibility of selectively targeting pathogenic stromal 474 
subpopulations mediating inflammation and tissue damage informs the development 475 
of future strategies to successfully treat joint disease.  476 
 477 
3.0 Shaping the future landscape: therapeutic targeting of 478 
mesenchymal cells  479 
 480 
Cells of mesenchymal origin including fibroblasts, TRM and endothelial cells 481 
constitute the major cell types populating joint soft tissues. We have discussed the 482 
roles and mechanisms by which these cells mediate joint inflammation, highlighting 483 
their ability to act as immune sensing sentinel  cells, their capacity for activation, 484 
positional memory and their altered phenotypes comprising multiple cellular sub-485 
populations. Multidirectional cross talk between stromal cell populations further fuels 486 
the development of persistent inflammation.  Given these important roles and 487 
associated biological complexities, it is likely that residual disease activity in patients 488 
treated with immune therapies may be attributable to stromal mediated inflammatory 489 
responses, which are refractory to current therapies that target immune cell 490 
populations 134. New therapeutic approaches are therefore required to ‘break the 491 
cycle and reset the system’, particularly in scenarios where inflammation becomes 492 
independent of the inciting stimulus. Given the limited capacity of joint tissues to 493 
regenerate once damaged, there are significant challenges associated with curbing 494 
tissue damage, which might be accomplished through moderating persistent 495 
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inflammation as a driver of fibrosis. We next discuss the requirement for future 496 
strategies to address the pathobiology concerned with the stromal 497 
microenvironment, targeting cells of mesenchymal origin. We review the drug 498 
classes in current clinical use, those in early phase clinical trials and strategies with 499 
pre-clinical potential to target stromal mediated joint disease. The cellular and 500 
molecular targets and the mechanism of action through which these drug classes 501 
function are summarized in Table 1.  502 
 503 
Existing licensed therapies  504 
 505 
Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids provide 506 
symptomtic relief for a broad array of conditions targeting inflammation and pain. 507 
Their clinical use in the management of a multitude of diseases affecting the joint is 508 
well established 135-138. These therapies target fibroblasts, TRM and endothelial cells 509 
via differing biological modes of action. Inhibition of COX activity by NSAIDs 510 
dampens release of prostaglandins, leukotrienes and thromboxane A2. 511 
Corticosteroids act via the glucocorticoid receptor to inhibit cPLA2, regulate 512 
expression of NFB / MAPK target genes and dampen release of inflammation 513 
initiating eicosanoids. Whilst NSAIDs and corticosteroids continue to provide 514 
background anti-inflammatory therapy for many rheumatic diseases, they are both 515 
associated with well documented adverse systemic effects. Importantly, COX-2 516 
selective NSAIDs also dampen protective endogenous resolution responses 139,140, 517 
which may paradoxically impede the capacity of inflamed joint tissues to heal. 518 
 519 
Monoclonal antibodies enable precise molecular targeting of cytokines mediating 520 
joint inflammation. The biological modes of action and efficacy of therapeutic 521 
inhibitors of IL-1, IL-6, TNF and IL-17 in current clinical use are well reported and 522 
listed in Table 1. One disadvantage associated with selective cytokine inhibition is 523 
the failure of this approach to fully target stromal mediated inflammatory responses 524 
and address the complex multidirectional cross talk between mesenchymal cell 525 
populations.  Similarly targeting chemokine gradients is an attractive strategy to 526 
moderate leukocyte retention 141. However chemokine antagonists including 527 
AMD3100 targeting CXCR4 are associated with adverse systemic effects 142 and the 528 
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plethora of chemokines mediating stromal inflammatory responses presents a further 529 
therapeutic challenge.   530 
 531 
Therapies in early phase clinical trials 532 
 533 
GM-CSF, predominantly produced by activated T cells, monocytes and 534 
macrophages is also released by tissue resident cells of mesenchymal origin 143. 535 
Humanised IgG1 monoclonal antibodies to GM-CSF prevent interaction of this 536 
cytokine with its receptor, reducing downstream signalling pathways converging on 537 
NFB. GM-CSF has shown potential as a therapeutic target in autoimmune and 538 
inflammatory disorders, including RA. Early phase clinical trials demonstrated 539 
disease activity scores reduced in mavrilimubab treated patients with moderate RA . 540 
Therapies targeting GM-CSF or its receptor have shown encouraging results in more 541 
recent pre-clinical studies and are reviewed in detail elsewhere 143. Recent phase IIb 542 
studies have demonstrated that long term mavrilimumab treatment maintained 543 
clinical responses and was well tolerated in RA patients with inadequate response to 544 
DMARD’s144. Further investigation is required to determine the efficacy of GM-CSF 545 
targeted therapies to modulate stromal mediated inflammatory responses in the joint.  546 
Kinase inhibitors targeting JAK and SYK signalling pathways have been investigated 547 
for their therapeutic utility to reduce cytokine release through JAK STAT 145,146 or 548 
MAPK / PKC 147,148 blockade respectively (Table 1). Baricitinib, an oral reversible 549 
inhibitor of JAK1 and JAK2 has shown therapeutic value in RA patients. This 550 
treatment was associated with significant clinical improvements in patients with an 551 
inadequate response to methotrexate compared with placebo and adalimumab 552 
treated groups 149. Protein kinase inhibitors target a broad range of cells types with 553 
reported off target effects, highlighting the importance of understanding the 554 
pharmacology of these drugs beyond the kinome 150.  555 
 556 
Potential future strategies to target pathogenic stroma 557 
 558 
Developments in cancer medicine targeting cancer associated fibroblasts populating 559 
tumour stroma have informed potential future strategies to target pathogenic stroma 560 
in rheumatic disease 151,152. Targeting pathogenic stroma presents a considerable 561 
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therapeutic challenge due to the biological complexity underpinning activation, 562 
memory and phenotypic diversity exhibited by these mesenchymal cell populations. 563 
Potential future strategies to treat residual rheumatic disease might include targeting 564 
activated fibroblast subtypes, use of epigenetic modifiers or resolution agonists to 565 
target stromal mediated inflammation. Pre-clinical evidence supporting these 566 
approaches are discussed below.  567 
 568 
Selective targeting of distinct fibroblast subtypes mediating joint inflammation and 569 
tissue damage is a potential therapeutic strategy to target pathogenic stroma. 570 
Cadherin-11 is known to regulate synovial fibroblast inflammation, synergizing with  571 
IL-1 and TNF to regulate IL-6 release 153.  This study showed that cad-11 deficient 572 
mice or anti–cad-11 mAb therapies reduced inflammation in arthritic mice, 573 
suggesting that cadherin expression regulates the inflammatory capacity of synovial 574 
fibroblasts. Cyclin dependent kinases regulate cell proliferation and survival via 575 
specific inhibitors (CDKi) and are potential therapies to target fibroblast 576 
accumulationproliferation in RA synovium (Table 1). CDK pathways become 577 
dysregulated in cancer, leading to the development of anti-cancer drugs including 578 
the CDKi Roscovitine 154. In synovial fibroblasts, IL-6 and MMP-1 are known to be 579 
regulated by CDKi p21 155. Given that CD34+CD90- ‘immunoregulatory’ fibroblasts 580 
are highly proliferative, invasive and produce IL-662, CDKi therapies are a potential 581 
strategy to target this fibrolast subset mediating joint disease.  582 
 583 
We previously discussed how epigenetic changes are implicated in mediating 584 
stromal fibroblast activation and memory. Epigenetic alterations in RA synovial 585 
fibroblasts are listed in Table 1, identifying DNA methylation, histone modification 586 
and miRNA as potential processes to therapeutically target 43,45-47,156. Moderating the 587 
epigenetic landscape is likely to have broad ranging effects on a variety of cell types, 588 
with off target effects. Hence improved understanding of the pharmacology of these 589 
drugs beyond the epigenome is essential before we can appreciate their potential 590 
utility to treat joint disease.  591 
 592 
The roles of proresolving mediators in joint health and disease are increasingly 593 
understood, identifying resolution agonists as potential therapies to moderate joint 594 
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inflammation and promote tissue repair 96.  The biological modes of action of 595 
proresolving mediators  or ‘immunoresolvents’ are well established from in vitro and 596 
in vivo studies and include limiting PMN infiltration, stimulating efferocytosis and 597 
activation of endogenous tissue protective mechanisms 90-93,157,158. Whilst 598 
immunoresolvents target leukocytes, their biological actions are not associated with 599 
immunosuppression 83,159. Importantly, proresolving mediators also target fibroblasts, 600 
TRM and endothelial cells types 160-162 and therefore possess the capacity to 601 
modulate stromal mediated inflammatory responses across joint tissues. Approaches 602 
to potentiate resolution processes include dietary supplementation with proresolving 603 
precursors, blocking catabolism of proresolving mediators or local delivery of stable 604 
analogues binding proresolving receptors 96. The pro-resolving mediator RvD3 was 605 
found to limit leukocyte infiltration and paw joint eicosanoid levels in murine 606 
inflammatory arthritis 163. The stable epimer 17R-RvD1 significantly attenuated 607 
arthritis severity, cachexia, paw oedema, leukocyte infiltration and shortened the 608 
remission interval, showing cartilage protective actions in murine models of acute 609 
inflammatory arthritis164.  In vitro studies also highlight the capacity of 15-epi-LXA4 610 
and MaR1 stable epimers to regulate PDPN, STAT-1 and IL-6 in IL-1 stimulated 611 
diseased human tendon stromal cells 35,165. Collectively these studies suggest 612 
resolution pharmacology may be an important future therapeutic tool to address 613 
stromal pathobiology in the joint.  614 
 615 
Conclusions 616 
 617 
Stromal cells of mesenchymal origin including fibroblasts, tissue resident 618 
macrophages and endothelial cells are pivotal populations regulating health and 619 
disease in musculoskeletal tissues. New insights are beginning to reveal the 620 
mechanisms underpinning the activation and dysfunction of mesenchymal stromal 621 
cells and their contribution to sustaining chronic joint inflammation. The discovery 622 
that distinct synovial fibroblast subsets mediate joint inflammation and damage will 623 
inform precision therapeutic targeting of pathogenic stromal cell populations. These 624 
discoveries shape the future therapeutic landscape, presenting exciting new 625 
approaches to address the pathogenic stromal microenvironment. Harnessing the 626 
capacity to modulate cross talk between leukocyte and pathogenic stromal cell 627 
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populations is a critical barrier to overcome in our quest to advance therapeutic 628 
strategies for patients with refractory joint disease.  629 
 630 
Glossary of terms 631 
 632 
Mesoderm: Middle embryonic primary germ layer residing between ectoderm and 633 
endoderm 634 
 635 
Mesenchymal: Embryonic connective tissue derived from the mesoderm 636 
 637 
Mesenchymal tissue: Tissue of the  musculoskeletal, circulatory and lymphatic 638 
systems 639 
 640 
Stromal cell: Non-haematopoietic, tissue resident cells. 641 
 642 
Stromal cell activation: Process whereby stromal cells including fibroblasts, tissue 643 
resident macrophages and endothelial cells adopt a pro-inflammatory phenotype and 644 
express distinct molecular markers after exposure to an inflammatory stimulus.  645 
 646 
Stromal cell memory: A change in the capacity of stromal cells to respond to 647 
inflammatory stimuli648 
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Table 1: Drugs to target the pathogenic stroma and associated immune cell 
cross talk in joint disease 
 
Drug Class Target 
Mesenchymal 
Cell 
Molecular 
Target 
Mechanism of Action References 
NSAIDs 
 
 
Fibroblast (F) 
Tissue Resident 
Macrophage (TRM) 
Endothelial Cell (EC) 
 
COX-1 
COX-2 
Selective / non-selective 
inhibition of COX to reduce 
release of prostaglandins, 
leukotrienes, thromboxane 
135,136
 
Corticosteroids 
 
 
F, TRM, EC glucocorticoid 
receptor 
cPLA2 inhibition 
regulate NFB / MAPK target 
genes 
reduce prostaglandins, 
leukotrienes, thromboxane 
 
137,138
 
 
Monoclonal Ab 
 
IL-1 
 
 
IL-6 
 
TNF 
 
 
GM-CSF 
 
 
IL-17 
 
 
TRM (F) 
 
 
TRM, F 
 
TRM (F) 
 
 
TRM, F, EC 
 
 
TRM 
 
 
IL-1R 
 
 
IL-6R 
 
TNFR 1/2 
 
 
GM-CSFR 
 
 
IL-17R family 
 
 
Reduce effects of 
inflammasome and caspase 
activation 
Reduce STAT-3 signalling 
 
Reduce NFB / MAPK 
signalling 
 
Reduce JAK STAT, PI3K, 
MAPK and NFB signalling 
 
Reduce TRAF6, MAPK, TAK1 & 
NFB signalling  
 
 
 
166,167
  
 
                
168-172
 
 
                
173-178
 
 
 
179,180
 
 
 
181-183
 
Kinase Inhibitors 
 
JAK inhibitors 
 
 
 
 
SYK inhibitors 
 
 
 
F, TRM 
 
 
 
F, TRM 
 
 
 
 
JAK1 JAK2 JAK3 
TYK2 
 
 
Fc receptor 
 
 
 
Blockade of cytokine signalling 
via JAK STAT 
 
 
Reduce IL-6 via MAPK / PKC 
 
 
 
 
145,146,149
 
 
 
                
147,148
 
 
Fibroblast activation 
 
Cadherin-11 mAb 
 
Cyclin dependent 
kinase inhibitors 
(CDKi) 
 
 
 
F 
 
F 
 
 
 
 
 
Cadherin-11 
 
CDK1,2,4,6 
 
 
Reduce MAPK, NFkB, IL-6 
 
Inhibit cell proliferation & 
survival, induce apoptosis 
 
 
153
 
 
 
142,154,155
 
 
Epigenetic Modifier 
 
 
 
 
 
 
F 
DNA methylation 
Histone 
modification 
 
 
miRNA 
 
 
 
Hypomethylation LBH enhancer 
region 
 
Increase H4 acetylation 
CXCL10 promoter 
Increase H4 acetylation IL-6 
promoter 
Reduce miR-22 
Reduce miR-20a 
Reduce miR203 
45,47,156
 
                   
                   
44
 
 
184
 
                  
185
 
186
 
187
 
Pro-resolving 
 
17-R RvD1 
 
Annexin A1 
 
 
RvD3 
 
 
 
15-epi-LXA4 
 
 
 
 
 
F, TRM, EC 
 
 
ALX, DRV1 
 
ALX 
 
 
ALX 
 
 
 
ALX 
 
 
Chondroprotective 
 
Chondroprotective, increased 
TGF, prevent apoptosis 
 
Reduce leukocyte infiltration, 
prostaglandins, leukotrienes 
and thromboxane 
 
Reduced STAT-1, IL-6, 
 
 
164
 
 
 
188
 
 
 
163
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Figures: 
 
Figure 1. Embryological origins of mesenchymal tissues in the whole joint 
organ.  
To further understand the mechanisms and inter-relationships underpinning 
inflammation and tissue damage across the joint, it is important to consider the 
embryonic origins of joint tissues, which may shape the behaviour of these cell types 
in diseased adult tissues. Embryonic Mesoderm is the precursor for mesenchymal 
tissues comprising the axial and appendicular skeleton, synovium, cartilage, 
tendons, ligaments, joint capsule and their associated lymphatics and vasculature. 
Adult joint soft tissues are predominantly composed of cells of mesenchymal origin, 
including fibroblasts, endothelial cells and tissue resident macrophages (TRM). The 
shared embryological origins of fibroblasts and endothelial cells shape the behavior 
of these cell types in diseased adult tissues in terms of their ability to exhibit 
activation and memory after exposure to inflammatory stimuli. Yolk sac derived TRM 
are phenotypicallygenetically distinct from HSC derived lineages. TRM occupy 
subspecialized niches which dictate their heterogeneity and phenotype in adult 
tissues. 
 
Figure 2. Molecular features of cells of mesenchymal origin in Rheumatoid 
pathological synovium. 
Inset shows topographical location of cell types comprising RA synovium, consisting 
of lining and sublining layers. Synovial lining fibroblasts (blue) are CD34-CD90-, 
express PDPN, CD55 and release MMP-1 and MMP-13 implicated in tissue 
destruction. Fibroblast subsets concerned with proliferation, accumulation and 
inflammationproliferation and inflammation occupy the synovial sublining. 
Proliferative Iimmunoregulatory fibroblasts (green) promote fibroblast accumulation 
and invasion. These cells express CD34 and release chemokines and cytokines 
generating gradients that promote leukocyte retention. Pathogenic fibroblasts (red) 
are a CD34-CD90+ subpopulation that highly express markers of stromal fibroblast 
activation and exhibit inflammationstromal memory. Pathogenic fibroblasts express 
TLR4 which mediates the damage sensing properties of these cells and downstream 
activation of the NFB pathway via MAPK, JNK and JAK-STAT signalling pathways. 
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These phenotypic features sustain the pro-inflammatory pathogenic phenotype of 
this fibroblast subset. Fibroblasts in the synovial sublining are in close proximity to 
activated endothelial cells,  expressing CD31, VCAM-1 and ICAM-1 and CD68+ 
tissue resident macrophages (TRM) which release pro-inflammatory mediators and 
proteases.  
 
Figure 3: Mechanisms sustaining synovial inflammation, highlighting cross 
talk between cells of mesenchymal origin and leukocytes.  
Cells of mesenchymal origin including fibroblast subsets, endothelial cells and tissue 
resident macrophages (TRM) are engaged in multidirectional cross talk, which 
sustains synovial inflammation. RA synovial fibroblasts promote leukocyte retention 
via release of cytokines and chemokine gradients and via contact with other cells of 
mesenchymal origin. Pro-inflammatory cytokines released by retained monocytes, T 
cells and TRM including IFN, TNF and IL-1 induce activated synovial fibroblasts 
to release high levels of PGE2, GM-CSF and IL-6. TGF released by TRM induces 
persistent expression of CXCR4 on synovial T cells, leading to their active CXCL12 
mediated retention. RA synovial fibroblasts also release chemokines including CCL2, 
CCL4, CCL5, CCL8, CXCL8, CXCL12 and IFN that promotes the recruitment, 
retention and survival of monocytes and CD4+ T cells. IL-6, TGF1 and VEGF 
released from TRM provide the necessary cues to promote an angiogenic 
environment required to sustain endothelial cell activation and dysfunction. The RA 
synovial fibroblast milieu further sustains an angiogenic environment through 
chemokine gradients comprising CXCL1-5 and CXCL8.  
 
